Reprogramming RelA

Cell Cycle

Volumn 3, Issue 7, 2004, Pages 867-870

  Campbell, Kirsteen J ^a   Perkins, Neil D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

ARF; Chemotherapy; Histone deacetylase; NF B; p53; p65; Repression; Transcription; Ultraviolet; UV C

Indexed keywords

DNA BINDING PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SUBUNIT; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR RELA;

CANCER THERAPY; CARCINOGENESIS; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; GENE REPRESSION; GENE TARGETING; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 13144261708     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.3.7.955     Document Type: Review

References (31)

1. Ghosh S, May MJ, Kopp EB. NF-κB and rel proteins: Evolutionarily conserved mediators of immune responses. Ann Rev Immunol 1998; 16:225-60.
2. Kucharczak J, Simmons MJ, Fan YJ, Gelinas, C. To be, or not to be: NF-κB is the answer - role of Rel/NF-κB in the regulation of apoptosis. Oncogene 2003; 22:8961-82.
3. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Ann Rev Immunol 2000; 18:621-3.
4. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001; 107:241-6.
5. Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. Oncogene 1999; 18:6853-66.
6. Ali S, Mann DA. Signal transduction via the NF-κB pathway: a targeted treatment modality for infection, inflammation and repair. Cell Biochem Fund 2004; 22:67-79.
7. Haefner B. NF-κB Arresting a major culprit in cancer. Drug Discov Today 2002; 7:653-63.
8. Tergaonkar V, Bottero V, Ikawa M, Li QT, Verma, IM. IκB kinase-independent IκBa degradation pathway: Functional NF-κB activity and implications for cancer therapy. Mol Cell Biol 2003; 23:8070-83.
9. Kato T, Delhase M, Hoffmann A, Karin M. CK2 is a C-terminal IκB kinase responsible for NF-κB activation during the UV response. Mol Cell 2003; 12:829-39.
10. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-κB. Mol Cell 2004; 13:853-65.
11. Huang TT, Feinberg SL, Suryanarayanan S, Miyamoto, S. The zinc finger domain of NEMO is selectively required for NF-κB activation by UV radiation and topoisomerase inhibitors. Mol Cell Biol 2002; 22:5813-25.
12. Bottero V, Busuttil V, Loubat A, Magne N, Fischel JL, Milano G, Peyron, JF. Activation of nuclear factor kB through the IKK complex by the topoisomerase poisons SN38 and doxombicin: A brake to apoptosis in HeLa human carcinoma cells. Cancer Res 2001; 61:7785-91.
13. Huang TT, Wuerzbrger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 2003; 115:565-76.
14. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-κB in p53-mediated programmed cell death. Nature 2000; 404:892-7.
15. 1 arrest and apoptosis in a pro-B cell line. J Biol Chem 1999; 274:8708-16.
16. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-κB and AP-1. Mol Cell 1998; 1:543-51.
17. Ricca A, Biroccio A, Trisciuoglio D, Cippitelli M, Zupi G, Del Bufalo D. RelA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Brit J Cancer 2001; 85:1914-21.
18. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W, Schmitz ML. The pro- or anti-apoptotic function of NF-κB is determined by the nature of the apoptotic stimulus. Eur J Biochem 2000; 267:3828-35.
19. Aleyasin H, Cregan SP, Iyirhiaro G, O'Hare MJ, Callaghan SM, Slack RS, Park DS. Nuclear factor-κB modulates the p53 response in neurons exposed to DNA damage. J Neurosci 2004; 24:2963-73.
20. Rocha S, Campbell KJ, Perkins ND. p53- and Mdm2-independent repression of NF-κB transactivation by the ARF tumor suppressor. Mol Cell 2003; 12:15-25.
21. Ashburner BP, Westerheide SD, Baldwin AS. The p65 (RelA) subunit of NF-κB interacts with the histone deacetylase (HDAC) compressors HDAC1 and HDAC2 to negatively regulate gene expression. Mol Cell Biol 2001; 21:7065-77.
22. Vermeulen L, De Wilde G, Notebaert S, Vanden Berghe W, Haegeman G. Regulation of the transcriptional activity of the Nuclear Factor-κB p65 subunit. Biochem Pharmacol 2002; 64:963-70.
23. Smartt HJM, Elder DJE, Hicks DJ, Williams NA, Paraskeva C. Increased NF-κB DNA binding but not transcriptional activity during apoptosis induced by the COX-2-selective inhibitor NS-398 in colorectal carcinoma cells. Brit J Cancer 2003; 89:1358-65.
24. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999; 274:26448-53.
25. De Bosscher K, Berghe WV, Vermeulen L, Plaisance S, Boone E, Haegeman G. Glucocorticoids repress NF-κB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc Natl Acad Sci USA 2000; 97:3919-24.
26. Ito K, Jazrawi E, Cosio BJ, Barnes PJ, Adcock IM. p65-activated histone acetyltransferase activity is repressed by glucocorticoids. J Biol Chem 2001; 276:30208-15.
27. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003; 421:639-43.
28. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R. Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-κB signaling. Cancer Res 1999; 59:3299-303.
29. Gapuzan MER, Yufit PV, Gilmore TD. Immortalized embryonic mouse fibroblasts lacking the RelA subunit of transcription factor NF-κB have a malignantly transformed phenotype. Oncogene 2002; 21:2484-92.
30. Perkins ND. NF-κB: Tumor promoter or suppressor? Trends Cell Biol 2004; 14:64-9.
31. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-κB in the resolution of inflammation. Nature Med 2001; 7:1291-7.